Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015 (2015), Article ID 602710, 8 pages
Research Article

Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study

1Unidad de Neurología y Neurofisiología, Complejo Hospitalario Torrecárdenas, Calle Hermandad de Donantes de Sangre S/N, 04009 Almería, Spain
2Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Avenida San Juan Bosco 15, 50009 Zaragoza, Spain
3Unidad de Neurología, Hospital de Llerena, Avenida Badajoz 1, 06900 Llerena, Badajoz, Spain
4Servicio de Neurología, Hospital Clínico Universitario San Cecilio, Calle Dr. Oloriz 16, 18012 Granada, Spain
5Servicio de Neurologia, Hospital Clínico San Carlos, Calle del Profesor Martín Lagos S/N, 28040 Madrid, Spain
6Servicio de Neurología, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071 Sevilla, Spain
7Servicio de Neurología, Hospital General Universitario de Valencia, Calle de la Casa Misericordia 12, 46014 Valencia, Spain

Received 28 June 2015; Revised 9 November 2015; Accepted 25 November 2015

Academic Editor: Ahmad Beydoun

Copyright © 2015 Pedro J. Serrano-Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. This study assesses the lifetime and active prevalence of epilepsy in Spain in people older than 18 years. Methods. EPIBERIA is a population-based epidemiological study of epilepsy prevalence using data from three representative Spanish regions (health districts in Zaragoza, Almería, and Seville) between 2012 and 2013. The study consisted of two phases: screening and confirmation. Participants completed a previously validated questionnaire (EPIBERIA questionnaire) over the telephone. Results. A total of 1741 valid questionnaires were obtained, including 261 (14.99%) raising a suspicion of epilepsy. Of these suspected cases, 216 (82.75%) agreed to participate in phase 2. Of the phase 2 participants, 22 met the International League Against Epilepsy’s diagnostic criteria for epilepsy. The estimated lifetime prevalence, adjusted by age and sex per 1,000 people, was 14.87 (95% CI: 9.8–21.9). Active prevalence was 5.79 (95% CI: 2.8–10.6). No significant age, sex, or regional differences in prevalence were detected. Conclusions. EPIBERIA provides the most accurate estimate of epilepsy prevalence in the Mediterranean region based on its original methodology and its adherence to ILAE recommendations. We highlight that the lifetime prevalence and inactive epilepsy prevalence figures observed here were compared to other epidemiological studies.